Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 9/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18067134 | 1.00 | BTN3A1 (0.58) | BTN3A1LMNATDP1POLBMEN1 | |
| SCHEMBL12746449 | 1.00 | BTN3A1 (0.58) | BTN3A1LMNATDP1POLBMEN1 | |
| SCHEMBL13921731 | 1.00 | BTN3A1 (0.58) | BTN3A1LMNATDP1POLBMEN1 | |
| SCHEMBL15765587 | 0.89 | BTN3A1 (0.47) | BTN3A1LMNAMEN1KMT2AELANE | |
| SCHEMBL19986758 | 0.89 | BTN3A1 (0.47) | BTN3A1LMNAMEN1KMT2AELANE | |
| SCHEMBL16015978 | 0.88 | BTN3A1 (0.60) | BTN3A1LMNATDP1POLBMEN1 | |
| SCHEMBL15765628 | 0.87 | BTN3A1 (0.48) | BTN3A1LMNAELANEHPGDALDH1A1 | |
| SCHEMBL14643286 | 0.87 | BTN3A1 (0.54) | BTN3A1LMNAMEN1KMT2ANPSR1 | |
| SCHEMBL20959996 | 0.87 | BTN3A1 (0.54) | BTN3A1LMNAMEN1KMT2ANPSR1 | |
| SCHEMBL13656424 | 0.87 | BTN3A1 (0.54) | BTN3A1LMNAMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676797-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170057981-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057981-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | BTN3A1 3253/4885LMNA 3478/4885TDP1 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.